UroGen Pharma Ltd. (URGN) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $135.00K; Additional Paid in Capital, Common StockUSD $865.11M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.00K; Retained Earnings (Accumulated Deficit)USD $-997.64M.
- 2026-03-31: Common Stock, Value, IssuedUSD $134.00K; Additional Paid in Capital, Common StockUSD $858.89M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $8.00K; Retained Earnings (Accumulated Deficit)USD $-983.29M.
- 2025-12-31: Common Stock, Value, IssuedUSD $133.00K; Additional Paid in Capital, Common StockUSD $854.09M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $19.00K; Retained Earnings (Accumulated Deficit)USD $-959.72M.
- 2025-09-30: Common Stock, Value, IssuedUSD $128.00K; Additional Paid in Capital, Common StockUSD $817.79M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $23.00K; Retained Earnings (Accumulated Deficit)USD $-933.35M.
UroGen Pharma Ltd. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Additional Paid in Capital USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $135.00K | $865.11M | $-2.00K | $-997.64M | $-132.40M | 3 month · $5.33M 6 month · $9.96M | (m) | (m) |
| 2026-03-31 | $134.00K | $858.89M | $8.00K | $-983.29M | $-124.25M | 3 month · $4.63M | (m) | (m) |
| 2025-12-31 | $133.00K | $854.09M | $19.00K | $-959.72M | $-105.47M | 12 month · $11.96M | (m) | (m) |
| 2025-09-30 | $128.00K | $817.79M | $23.00K | $-933.35M | $-115.41M | 3 month · $3.03M 9 month · $8.83M | (m) | (m) |
| 2025-06-30 | $126.00K | $806.50M | $6.00K | $-900.00M | $-93.38M | 3 month · $2.73M 6 month · $5.80M | (m) | (m) |
| 2025-03-31 | $126.00K | $803.47M | $14.00K | $-850.07M | $-46.46M | 3 month · $3.07M | (m) | (m) |
| 2024-12-31 | $115.00K | $797.25M | $56.00K | $-806.22M | $-8.80M | 12 month · $13.11M | 12 month · $18.64M | (m) |
| 2024-09-30 | $115.00K | $793.87M | $236.00K | $-768.71M | $25.52M | 3 month · $3.49M 9 month · $9.80M | 9 month · $18.64M | (m) |
| 2024-06-30 | $112.00K | $775.27M | $-31.00K | $-745.04M | $30.31M | 3 month · $3.56M 6 month · $6.32M | 3 month · $18.64M 6 month · $18.64M | (m) |
| 2024-03-31 | $99.00K | $671.44M | $-37.00K | $-711.63M | $-40.13M | 3 month · $2.76M | (m) | (m) |
| 2023-12-31 | $89.00K | $614.03M | $12.00K | $-679.35M | $-65.21M | 12 month · $9.34M | 12 month · $48.70M | (m) |
| 2023-09-30 | $84.00K | $611.39M | $-134.00K | $-653.33M | $-41.99M | 3 month · $2.22M 9 month · $6.73M | 3 month · $48.70M 9 month · $48.70M | (m) |
| 2023-06-30 | $64.00K | $493.11M | $-154.00K | $-631.45M | $-138.43M | 3 month · $2.22M 6 month · $4.51M | (m) | (m) |
| 2023-03-31 | $64.00K | $490.74M | $-45.00K | $-607.32M | $-116.55M | 3 month · $2.29M | (m) | (m) |
| 2022-12-31 | $63.00K | $487.79M | $-107.00K | $-577.10M | $-89.36M | 12 month · $10.58M | (m) | (m) |
| 2022-09-30 | $63.00K | $485.04M | $-155.00K | $-548.24M | $-63.29M | 3 month · $2.44M 9 month · $8.21M | (m) | (m) |
| 2022-06-30 | $62.00K | $481.49M | $-56.00K | $-522.40M | $-40.91M | 3 month · $2.82M 6 month · $5.77M | (m) | (m) |
| 2022-03-31 | $62.00K | $478.65M | $-69.00K | $-495.71M | $-17.07M | 3 month · $2.95M | (m) | (m) |
| 2021-12-31 | $61.00K | $475.70M | $-25.00K | $-467.32M | $8.41M | 12 month · $23.11M | (m) | (m) |
| 2021-09-30 | $61.00K | $470.34M | $4.00K | $-438.87M | $31.54M | 3 month · $5.51M 9 month · $17.76M | (m) | (m) |
| 2021-06-30 | $61.00K | $464.82M | $45.00K | $-408.66M | $56.27M | 3 month · $6.05M 6 month · $12.24M | (m) | (m) |
| 2021-03-31 | $61.00K | $458.72M | $143.00K | $-382.44M | $76.49M | 3 month · $6.20M | (m) | (m) |
| 2020-12-31 | $60.00K | $452.52M | $271.00K | $-356.50M | $96.36M | 12 month · $28.02M | (m) | (m) |
| 2020-09-30 | $60.00K | $445.95M | $492.00K | $-325.98M | $120.53M | 3 month · $6.76M 9 month · $21.50M | (m) | (m) |
| 2020-06-30 | $60.00K | $439.00M | $760.00K | $-297.16M | $142.66M | 3 month · $7.12M 6 month · $14.74M | (m) | (m) |
| 2020-03-31 | $58.00K | $415.89M | $311.00K | $-265.81M | $150.45M | 3 month · $7.62M | (m) | (m) |
| 2019-12-31 | $57.00K | $407.99M | $276.00K | $-228.02M | $180.30M | 12 month · $29.97M | (m) | (m) |
| 2019-09-30 | $57.00K | (m) | $303.00K | $-189.04M | $210.92M | 3 month · $7.24M 9 month · $21.90M | (m) | $399.60M |
| 2019-06-30 | $57.00K | (m) | $281.00K | $-166.79M | $224.78M | 3 month · $7.21M 6 month · $14.66M | (m) | $391.23M |
| 2019-03-31 | $56.00K | (m) | (m) | $-144.31M | $239.59M | 3 month · $7.45M | (m) | $383.85M |
| 2018-12-31 | $44.00K | $212.92M | (m) | $-122.87M | $90.09M | 12 month · $30.64M | (m) | $212.92M |
| 2018-09-30 | $44.00K | (m) | (m) | $-99.15M | $103.58M | 3 month · $9.52M 9 month · $21.77M | (m) | $202.69M |
| 2018-06-30 | $43.00K | (m) | (m) | $-78.62M | $113.55M | 3 month · $7.71M 6 month · $12.25M | (m) | $192.13M |
| 2018-03-31 | $42.00K | (m) | (m) | $-60.60M | $123.87M | 3 month · $4.54M | (m) | $184.42M |
| 2017-12-31 | $37.00K | (m) | (m) | $-47.21M | $68.52M | 12 month · $6.30M | (m) | $115.69M |
| 2017-09-30 | (m) | (m) | (m) | (m) | $76.26M | 9 month · $4.03M | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | $74.07M | 6 month · $1.87M | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | $13.19M | 3 month · $297.00K | (m) | (m) |
| 2016-12-31 | $6.00K | (m) | (m) | $-27.21M | $16.31M | 12 month · $1.97M | (m) | $43.50M |
| 2015-12-31 | (m) | (m) | (m) | (m) | $16.28M | 12 month · $449.00K | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | $3.16M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |